PM
VIR icon

Parametrica Management’s Vir Biotechnology VIR Stock Holding History

Parametrica Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,823
Closed -$201K – 310
2022
Q1 		$201K Buy
+7,823
New +$232K 0.15% 203

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Parametrica Management's VIR Position: Q2 2022 in Review

Parametrica Management sold out of Vir Biotechnology (VIR) in Q2 2022, closing a stake of 7,823 shares — an estimated $201K sold.

Parametrica Management first reported a position in VIR in Q1 2022 and held it in 1 quarter. The position peaked at $201K in Q1 2022. 212 funds tracked by Wall St. Rank hold VIR as of Q2 2022.

  • Parametrica Management reported no remaining Vir Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Parametrica Management sold 7,823 Vir Biotechnology shares in Q2 2022, an estimated $201K.
  • Parametrica Management first reported a position in Vir Biotechnology in Q1 2022 and held it in 1 quarter.
  • Parametrica Management's Vir Biotechnology position peaked at $201K in Q1 2022.
  • 212 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2022.

Based on Parametrica Management's 13F filing for Q2 2022, filed 22 Jul 2022.